Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:66:149-174.
doi: 10.1007/7854_2023_451.

Psilocybin and Other Classic Psychedelics in Depression

D J Nutt  1 , J M Peill  2 , B Weiss  2 , K Godfrey  2 , R L Carhart-Harris  2   3 , D Erritzoe  2
Affiliations
Review

Psilocybin and Other Classic Psychedelics in Depression

D J Nutt et al. Curr Top Behav Neurosci. 2024.

Abstract

Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target the 5-HT2A receptor such as psilocybin and DMT. These produce plasma-concentration related psychological effects such as hallucinations and out of body experiences, insightful and emotional breakthroughs as well as mystical-type experiences. When coupled with psychological support, effects can produce a rapid improvement in mood among people with depression that can last for months. In this chapter, we summarise the scientific studies to date that explore the use of psychedelics in depressed individuals, highlighting key clinical, psychological and neuroimaging features of psychedelics that may account for their therapeutic effects. These include alterations in brain entropy that disrupt fixed negative ruminations, a period of post-treatment increased cognitive flexibility, and changes in self-referential psychological processes. Finally, we propose that the brain mechanisms underlying the therapeutic effect of serotonergic psychedelics might be distinct from those underlying classical serotonin reuptake-blocking antidepressants.

Keywords: Antidepressants; Connectivity; Depression; Dimethyltryptamine (DMT); Electroencephalograhy (EEG); Entropy; Lysergic acid diethylamide (LSD); Magnetic resonance imaging (MRI); Modularity; Neuroimaging; Psilocybin; Psychedelics; Serotonin; Serotonin 2A receptor (5-HT2AR).

PubMed Disclaimer

References

    1. Abuse S (2021) Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56)
    1. Adamson S, Metzner R (1988) The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice. Revision 10(4):59–72
    1. Aday JS, Davis AK, Mitzkovitz CM, Bloesch EK, Davoli CC (2021) Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci 4(2):424–435 - PMC
    1. Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD (2022) Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl):1–22
    1. Agin-Liebes G, Zeifman R, Luoma JB, Garland EL, Campbell WK, Weiss B (2022) Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. J Psychopharmacol 36(3):295–308 - PMC

LinkOut - more resources